Perspective Therapeutics (CATX) Raw Materials (2011 - 2023)

Perspective Therapeutics has disclosed Raw Materials across 11 years of filings, most recently posting $764000.0 for Q3 2023.

• Raw Materials for Q3 2023 came in at $764000.0, down 16.23% year-over-year; the trailing twelve-month figure through Sep 2023 was $764000.0 (down 16.23% YoY), and the FY2022 annual result was $752000.0, changed N/A from the prior year.
• Raw Materials came in at $764000.0 for Q3 2023 at Perspective Therapeutics, down from $781000.0 in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $912000.0 in Q3 2022 to a low of $330000.0 in Q3 2019.
• The 5-year median for Raw Materials is $645000.0 (2021), against an average of $598105.3.
• Across the five-year window, Raw Materials jumped 98.69% in 2021 and slipped 16.23% in 2023, its largest moves.
• Perspective Therapeutics' Raw Materials stood at $372000.0 in 2019, then advanced by 20.43% to $448000.0 in 2020, then jumped by 67.63% to $751000.0 in 2021, then grew by 0.13% to $752000.0 in 2022, then grew by 1.6% to $764000.0 in 2023.
• The last three Raw Materials figures came in at $764000.0 (Q3 2023), $781000.0 (Q2 2023), and $777000.0 (Q1 2023), per Business Quant data.